Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA ...

Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your ...

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your ...

Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...

The SOL-R registrational trial (NCT06495918) of OTX-TKI (AXPAXLI) by Ocular Therapeutix has reached its randomization target of 555 patients.

AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was co-led by a new lead, Schroders Capital, as well as existing investors Atlas ...

Marguerite B. McDonald, MD, FACS, reflects on a first-year residency case that taught her the importance of trusting her ...

Deborah Ristvedt, DO, recalls a retinal detachment repair that took an unexpected turn, teaching lasting lessons in patient ...

The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies.

In the week following the announcement of this acquisition, Sanro Health, Inc. is reported to have made an investment in ...

ONL Therapeutics announced the first patient has been randomized in its phase 2 GALAXY ( NCT06659445) trial evaluating ...